SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to discussions around a potential $2 billion offering and insider selling, sparking debate about dilution and the company's valuation. While some community members view the offering as bullish, citing a premium price and warrants, others express concern about a potential bubble and the impact on existing shareholders. The conversation also includes comparisons to other quantum computing stocks and broader market trends.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to positive earnings, a raised price target from Needham, and news of a massive AI lease deal with CoreWeave. The community is discussing the potential for a short squeeze and future hyperscaler deals, with some bulls projecting significant gains while bears warn of overvaluation. Overall, sentiment is bullish, driven by the company's growth in the AI data center space.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending due to a strategic partnership focused on developing quantum-resistant chips for U.S. defense applications, igniting discussions about future government contracts. The community is actively evaluating the company's growth potential relative to other quantum computing stocks. Many investors are describing LAES as undervalued with potential for a significant upward trajectory.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss the potential for a short squeeze, fueled by high short interest and recent positive developments, including a partnership with Google. Community members are closely monitoring resistance levels and anticipating a breakout, drawing comparisons to other AI and high-performance computing data center plays. The focus remains on the company's transition towards AI infrastructure and its potential for growth in the sector.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as traders debate whether its recent surge is justified by fundamentals or fueled by a short squeeze, with community members highlighting both bullish and bearish arguments.  The launch of a new 2x short ETF (RGTZ) has added another layer to the discussion, as some believe it will exacerbate the squeeze while others see it as a sign of an impending reversal.  Quantum computing stocks are also in focus, and the community is comparing RGTI's valuation and potential against competitors.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as investors react to recent news, including a new multi-launch agreement with Japan's iQPS. The community is actively discussing the potential impact of this deal, along with speculation about upcoming catalysts like the Neutron launch and potential government contracts. Some traders caution about short-term overvaluation, while long-term bulls remain confident in the company's growth prospects.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as discussions revolve around its potential to catch up with other miners like CLSK and IREN, with some expressing frustration over its underperformance and management. Community members are debating whether its current valuation reflects its Bitcoin holdings and future AI prospects. Short interest remains high, fueling speculation about a potential squeeze.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is surging, fueled by speculation around a potential ETF and positive technical indicators, leading to renewed interest in the crypto asset. The community is actively discussing price targets and potential breakouts, while also debating whether this rally will be sustained. Some traders are pointing to Litecoin's historical performance relative to Bitcoin, suggesting it is undervalued.

One & One Green Technologies, Inc. engages in the recycle, production and trade of scrap metals. Its products include copper alloy ingot, aluminum scrapes, and plastic beads. The company was founded on April 17, 2024 and is headquartered in Bulacan, Philippines.

One and one Green Technologies. Inc - Ordinary Shares - Class A

Fueled by its recent IPO, $YDDL is trending due to significant after-hours volatility and a low float, leading to speculation of a potential massive run. The stock's connection to AI and green technology is adding to the excitement, though some traders express concerns about it being a pump and dump. Community members are actively discussing potential price targets and whether the stock can maintain its momentum.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as traders discuss its potential in the quantum computing sector, particularly compared to peers like $IONQ and $RGTI. The community highlights Infleqtion's existing contracts, partnership with NVIDIA, and a potential for significant upside, while some anticipate a near-term run to $30+ and compare it to previous high-flying SPACs. Chatter also mentions upcoming events and presentations, further fueling interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35.&nbsp;The firm said recent stumbles in Schrodinger’s homegrown drug programs, along with persistent headwinds across biotech and pharma, have dimmed its outlook.<a href="https://stocktwits.com/symbol/SDGR">Shares of Schrodinger</a> fell 2% to $19.45 on Thursday, marking its lowest close in four months, before edging up 0.2% to $19.5 in after-hours trading.The downgrade by the brokerage firm came just after Schrodinger disclosed that it will&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/schrodinger-discontinues-clinical-program-after-two-patient-deaths/chsR0RyRdOb">discontinue the development of SGR-2921</a>, an early-stage CDC7 inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.Chief Medical Officer Margaret Dugan said patient safety was the company’s top priority, noting that the drug’s potential as a combination therapy would be challenging to pursue under the circumstances. “While disappointing given the early clinical activity observed, we believe this is the right decision for patients,” she said.Citi said its earlier bullish stance had hinged on three early-stage Phase 1 assets that could validate Schrodinger’s drug discovery platform and attract biopharma partners.&nbsp;The brokerage firm noted that updates so far have “fallen short,” fueling concerns about the future of the company’s internal drug portfolio.SGR-2921 was&nbsp;designed to block CDC7 kinase, a protein overexpressed in many cancers and involved in DNA replication and cell cycle progression.&nbsp;Preclinical data had suggested the drug could work in combination with standard-of-care agents, but Schrodinger said the safety risks outweighed the potential benefits.On Stocktwits, retail sentiment for Schrodinger was ‘bearish’ amid ‘extremely high’ message volume.One user questioned the timing of Schrodinger’s disclosure, noting that the company reported Q2 earnings just eight days ago, and&nbsp;wondered if both patient deaths occurred since then or if the information had been withheld.&nbsp;<stembedurl>https://stocktwits.com/scott52/message/625133866</stembedurl>Another user speculated that there was “more to the news” than disclosed, pointing to the stock’s quick price recovery as a sign that “something fishy” might be going on.<stembedurl>https://stocktwits.com/Buckanator/message/625153259</stembedurl>Schrodinger’s stock has risen 0.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Schrodinger logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern

Shares closed at a four-month low before edging slightly higher after hours as investors digested the pipeline setback and cautious outlook.

Equity

Schrödinger, Inc. (SDGR) announced on Thursday that it is discontinuing the clinical development program for SGR-2921, which was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.The decision was made in light of two treatment-related deaths in the early-stage study, the company said. <a href="https://stocktwits.com/symbol/SDGR">Schrödinger</a> opined that developing the drug as a combination therapy would be difficult to pursue in light of the two deaths despite evidence of activity as a monotherapy.Margaret Dugan, chief medical officer at Schrödinger, <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Announces-Discontinuation-of-SGR-2921-Program/default.aspx">said</a>, “Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients.”On Stocktwits, retail sentiment around SDGR fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. The stock is trading 4% lower in the pre-market session on Thursday.Dugan said the company had hoped to advance the investigational drug for acute myeloid leukemia, a rapidly progressing cancer of the blood and bone marrow, provided there are limited therapies available for the disease. The early-stage study was also supported by preclinical data, which suggested that SGR-2921 could ultimately be used in combination with standard-of-care agents, the company said.SGR-2921 is a CDC7 inhibitor, meaning it is a drug that blocks the activity of the CDC7 kinase, a protein involved in DNA replication and cell cycle progression. CDC7 is often overexpressed in cancer cells, and its inhibition can lead to cell cycle arrest and programmed cell death of these cancer cells.SDGR stock is up by 3% this year and by over 4% in the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-as-investors-await-wholesale-inflation-data/chsRirXRdOG">Dow Futures Edge Lower As Wall Street Watches Out For PPI Report: BLSH, COHR, CSCO Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Schrödinger Discontinues Clinical Program After Two Patient Deaths

SGR-2921 was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

Schrodinger (SDGR) delivered earnings and revenue surprises of +28.92% and +5.08%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 0.00% and -1.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?

VEEV leans on Vault R&D for growth as AI-native rivals rise, testing its edge in clinical and regulatory innovation.

Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.

Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$20.32
Prev Close	$20.65
Open	$20.73
Dividend Yield	0.00%
50-Day Moving Average	$19.59
Beta	1.61
Avg. Volume	1.04M
PE Ratio	-8.32

52-Week High	$28.47
52-Week Low	$16.60
Market Capitalization	$1.52B
EPS (Annual)	-$2.58
Price to Book	4.43
Revenue Per Employee	$232,928.17
Enterprise Value/EBITDA	N/A

SDGR
Schrodinger Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SDGR News

SDGRSchrodinger Inc